Is PTC Therapeutics, Inc. (PTCT) a Buy, Sell, or Hold?
PTC Therapeutics, Inc.
NASDAQ:PTCT
$78.84 USD
$0.78 (1.0%)
- Volume
- 1.26M
- Average Volume
- 1.83M
- Market Capitalization
- $6.54B
- P/E Ratio
- -33.78
- Dividend Yield
- 0.00%
- Price Target
- $90.00
- Year High
- $90.87
- Year Low
- $43.18
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.44
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Matthew Klein |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PTCT |
| CUSIP | 69366J200 |
| CIK | 0001070081 |
| Web | https://www.ptcbio.com |
| Phone | 908 222 7000 |
| Currency | USD |
| Employees | 991 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -2.19 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.44 |
| Quick Ratio | 2.36 |
| Cash Ratio | 0.90 |
Sales & Book Value
| Annual Sales | $1.73B |
| Price / Sales | 7.91 |
| Cash Flow | -3.20 |
| Price / Cash Flow | -24.77 |
| Price / Book | -36.05 |
Price Target and Rating
| Average Stock Price Forecast | $90.00 |
| High Stock Price Forecast | $120.00 |
| Low Stock Price Forecast | $85.00 |
| Forecast Upside/Downside | -12.40% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 26 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $7.78 |
| Trailing P/E Ratio | -33.78 |
| PEG Ratio | 0.26 |
| P/E Growth | 0.26 |
| Net Income | $682.64M |
| Net Margin | -22.58% |
| Pretax Margin | -28.49% |
| Return on Equity | 99.84% |
| Return on Assets | -6.51% |
Financials Score
| AltmanZ Score | 0.53 |
| Piotroski Score | 1.00 |
| Working Capital | 1.33B |
| Total Assets | 2.87B |
| Ebit | -166.56M |
| Market Cap | 6.75B |
| Total Liabilities | 3.05B |
Poll Results
About PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionall ... y commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
2026-07-13 19:28:52
The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider's direct common stock holdings.
Reasons Why Investors Should Consider Betting on PTC Stock Now
2026-07-10 15:16:06
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Stocks Look Shaky, But This Sector is Booming (Biotech)
2026-07-09 14:06:06
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
2026-07-08 13:01:07
PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
2026-07-02 10:36:08
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
2026-06-18 09:21:03
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-17 16:30:00
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
2026-06-16 00:00:00
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire
Frequently Asked Questions
-
What is the current PTC Therapeutics, Inc. (PTCT) stock price?
-
PTC Therapeutics, Inc.(NASDAQ:PTCT) stock price is $78.84 in the last trading session. During the trading session, PTCT stock reached the peak price of $90.87 while $43.175 was the lowest point it dropped to. The percentage change in PTCT stock occurred in the recent session was 1.0% while the dollar amount for the price change in PTCT stock was $0.78.
-
PTCT's industry and sector of operation?
-
The NASDAQ listed PTCT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PTCT?
-
Allan Steven Jacobson | Co-Founder & Independent Director
Lee Golden | Executive Vice President & Chief Medical Officer
Matthew Klein | Chief Executive Officer & Director
Neil Almstead | Chief Technical Operations Officer
Eric Pauwels | Chief Business Officer -
How many employees does PTCT have?
-
Number of PTCT employees currently stands at 991. PTCT operates from 100 Corporate Court, Warren, NJ 07080, US.
-
Link for PTCT official website?
-
Official Website of PTCT is: https://www.ptcbio.com
-
How do I contact PTCT?
-
PTCT could be contacted at phone #908 222 7000 and can also be accessed through its website. PTCT operates from 100 Corporate Court, Warren, NJ 07080, US.
-
How many shares of PTCT are traded daily?
-
The average number of PTCT shares traded daily for last 3 months was 1.83M.
-
What is the market cap of PTCT currently?
-
The market value of PTCT currently stands at $6.54B with its latest stock price at $78.84